PDO
Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Breast Cancer Patients With Brain and/or Extra-cranial Metastases
Sponsor study identifier
observational
20
1 country
2
Study Start
May 27, 2025
Actual (reported)Primary Completion
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients' treatment response and their radio-sensitivity and chemo-sensitivity can be correlated with their survival outcome.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 4, 2024
Actual (reported)June 21, 2024
Actual (reported)May 27, 2025
Actual (reported)June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Patient derived organoids
To generate PDOs from brain or extra-cranial metastases of breast cancer patients.
10 months
Response to radiotherapy
6 months
Response to therapy
5 months
recurrence and survival rates
4 months
Response rate of patients undergoing systemic treatment
3 months
Breast cancer patients with brain metastases undergoing surgical resection with or without further radiotherapy (SRS or whole brain radiotherapy)
Breast cancer patients with extra-cranial metastases undergoing surgical resection or biopsy
Breast cancer patients with resectable brain or extra-cranial metastases and undergoing postoperative radiotherapy or palliative radiotherapy to extracranial metastases if necessary +/- other systemic treatments after resection. Patients who will undergo a biopsy of the extra-cranial metastases may be recruited and asked to consent for an additional research biopsy at the same time as standard of care biopsy.
Guy's and St. Thomas NHS Foundation Trust
London, SE1 9RT, United Kingdom
King's College Hospital NHS Foundation Trust
London, SE5 9RS, United Kingdom
Tumour and normal tissues, blood, saliva, oral swabs, urine and stool
Anthony Kong
Clinical reader and honorary NHS consultant in clinical oncology
First Submitted
June 4, 2024
First Posted
June 21, 2024
Study Start
May 27, 2025
Actual (reported)Primary Completion
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
Contact the study team to confirm eligibility.
Study Completion
June 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 22, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: